

# Xiaoxiao Guo

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6503073/xiaoxiao-guo-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

36  
papers

254  
citations

8  
h-index

14  
g-index

45  
ext. papers

384  
ext. citations

4  
avg, IF

3.12  
L-index

| #  | Paper  | IF   | Citations |
|----|--|------|-----------|
| 36 | Effect of Sacubitril/Valsartan on the Right Ventricular Function and Pulmonary Hypertension in Patients With Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis of Observational Studies.. <i>Journal of the American Heart Association</i> , <b>2022</b> , e024449 | 6    | 1         |
| 35 | Predictive value of heart rate in patients with acute type A aortic dissection: a retrospective cohort study. <i>BMJ Open</i> , <b>2021</b> , 11, e047221  | 3    |           |
| 34 | Myocarditis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e14579-e14579   | 2.2  |           |
| 33 | Oxidation of Ryanodine Receptors Promotes Ca Leakage and Contributes to Right Ventricular Dysfunction in Pulmonary Hypertension. <i>Hypertension</i> , <b>2021</b> , 77, 59-71   | 8.5  | 6         |
| 32 | Mep1a contributes to Ang II-induced cardiac remodeling by promoting cardiac hypertrophy, fibrosis and inflammation. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2021</b> , 152, 52-68   | 5.8  | 4         |
| 31 | Role of IgE-Fc $\beta$ 1 in Pathological Cardiac Remodeling and Dysfunction. <i>Circulation</i> , <b>2021</b> , 143, 1014-1030   | 16.7 | 6         |
| 30 | Predictive value of non-invasive right ventricle to pulmonary circulation coupling in systemic lupus erythematosus patients with pulmonary arterial hypertension. <i>European Heart Journal Cardiovascular Imaging</i> , <b>2021</b> , 22, 111-118   | 4.1  | 8         |
| 29 | SARS-CoV-2 leads to myocardial injury in rhesus macaque. <i>Signal Transduction and Targeted Therapy</i> , <b>2021</b> , 6, 338  | 21   | 1         |
| 28 | Ventricular arrhythmia predicts poor outcome in polymyositis/dermatomyositis with myocardial involvement. <i>Rheumatology</i> , <b>2021</b> , 60, 3809-3816  | 3.9  | 1         |
| 27 | Cardiac Involvement in Eosinophilic Granulomatosis With Polyangiitis: A Retrospective Study in the Chinese Population. <i>Frontiers in Medicine</i> , <b>2020</b> , 7, 583944  | 4.9  | 4         |
| 26 | Clinical diagnosis and treatment of immune checkpoint inhibitor-associated adverse events in the digestive system. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 829-834  | 3.2  | 3         |
| 25 | Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 799-804  | 3.2  | 13        |
| 24 | Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 810-818   | 3.2  | 11        |
| 23 | Clinical diagnosis and treatment of immune checkpoint inhibitors-related endocrine dysfunction. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 1099-1104   | 3.2  | 2         |
| 22 | Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 805-809  | 3.2  | 3         |
| 21 | Management of immune checkpoint inhibitor-related adverse events: A review of case reports. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 498-504   | 3.2  | 6         |
| 20 | Management of immune checkpoint inhibitor-related dermatologic adverse events. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 488-492  | 3.2  | 6         |

|    |  |     |    |
|----|--|-----|----|
| 19 | Management of immune checkpoint inhibitor-related rheumatic adverse events. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 198-202   | 3.2 | 1  |
| 18 | Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 191-197   | 3.2 | 26 |
| 17 | Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 475-480   | 3.2 | 3  |
| 16 | Use of glucocorticoids in the management of immunotherapy-related adverse effects. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 3047-3052  | 3.2 | 6  |
| 15 | Predictive Value of Pulmonary Arterial Compliance in Systemic Lupus Erythematosus Patients With Pulmonary Arterial Hypertension. <i>Hypertension</i> , <b>2020</b> , 76, 1161-1168   | 8.5 | 4  |
| 14 | Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor-associated adverse events. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 2077-2086  | 3.2 | 0  |
| 13 | Top 100 most-cited articles on echocardiography: A bibliometric analysis. <i>Echocardiography</i> , <b>2019</b> , 36, 1540-1548  | 1.5 | 5  |
| 12 | The octopus on a heart. <i>European Heart Journal</i> , <b>2019</b> , 40, 635  | 9.5 | 1  |
| 11 | Is it possible to apply the treat-to-target strategy in primary Sjögren's syndrome-associated pulmonary arterial hypertension?. <i>Clinical Rheumatology</i> , <b>2018</b> , 37, 2989-2998   | 3.9 | 5  |
| 10 | The Relationship of Serum Antigen-Specific and Total Immunoglobulin E with Adult Cardiovascular Diseases. <i>International Journal of Medical Sciences</i> , <b>2018</b> , 15, 1098-1104   | 3.7 | 2  |
| 9  | Red blood cell distribution width as a related factor of pulmonary arterial hypertension in patients with systemic sclerosis. <i>Clinical Rheumatology</i> , <b>2018</b> , 37, 979-985   | 3.9 | 12 |
| 8  | Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: A cohort study in China. <i>International Journal of Cardiology</i> , <b>2017</b> , 236, 432-437                | 3.2 | 48 |
| 7  | A Case of Novel Lamin A/C Mutation Manifesting as Atypical Progeroid Syndrome and Cardiomyopathy. <i>Canadian Journal of Cardiology</i> , <b>2016</b> , 32, 1166.e29-31  | 3.8 | 4  |
| 6  | Serum IgE levels are associated with coronary artery disease severity. <i>Atherosclerosis</i> , <b>2016</b> , 251, 355-360   | 3.1 | 24 |
| 5  | Preoperative immunosuppressive therapy reduces paravalvular leakage after aortic valve surgery in patients with aortic regurgitation attributable to Behçet's disease. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, S26-S33 | 2.2 | 1  |
| 4  | Oxidation- and CaMKII-mediated sarcoplasmic reticulum Ca(2+) leak triggers atrial fibrillation in aging. <i>Journal of Cardiovascular Electrophysiology</i> , <b>2014</b> , 25, 645-52   | 2.7 | 17 |
| 3  | A novel dystrophin deletion mutation in a becker muscular dystrophy patient with early-onset dilated cardiomyopathy. <i>Canadian Journal of Cardiology</i> , <b>2014</b> , 30, 956.e1-3  | 3.8 | 5  |
| 2  | Giant aortic pseudoaneurysm fistulized into right atrium. <i>European Heart Journal</i> , <b>2012</b> , 33, 1733   | 9.5 | 1  |

- 1 Echocardiographic characteristics of intravenous leiomyomatosis with intracardiac extension: a single-institution experience. *Echocardiography*, **2011**, 28, 934-40 1.5 12